Oravax Medical, a subsidiary of Oramed Pharmaceuticals in Israel, received clearance from the South African Health Products Regulatory Authority to begin testing their oral Covid-19 vaccine.
CEO Nadav Kidron said, “We believe that Oravax’s oral COVID-19 vaccine candidate could offer an exciting potential solution to the COVID pandemic, whether as a booster or for the unvaccinated.” He continued, “An oral COVID-19 vaccine would eliminate several barriers to rapid, wide-scale distribution, potentially enabling people to administer the vaccine themselves at home.”
The intentions of Oravax Medical is to complete a Phase I trial and immediately transition into a Phase II/III trial, then apply for emergency approval.
Their vaccine is based on Oramed’s “POD” technology and Prema’s vaccine. The oral delivery technology is designed to be able to orally administer protein-based therapies which would normally be delivered via injection, and Premas has been working on a vaccine for Covid since March.
Kidron said, “The Oravax vaccine candidate targets three structural proteins of the novel coronavirus, as opposed to the single spike protein targeted by the current Moderna and Pfizer vaccines.” He continues, “As such, this vaccine should be much more resistant to Covid-19 variants. Even if the virus gets through one line, there is a second line, and through the second line, there is a third.”
Be sure to check back with the ABN Blog regularly for more updates.